Axpaxli edges Eylea on vision retention with fewer injections, but durability gap narrows
TL;DR
Ocular Therapeutix reported that Axpaxli met a key endpoint in a Phase 3 wet AMD trial by maintaining patients’ vision with fewer injections than the standard treatment. At 9 and 12 months after a single injection, 74% and 66% of Axpaxli patients maintained vision versus 56% and 44% for low-dose Eylea. While the primary goal was achieved, the durability advantage over Eylea was smaller than investors expected, which could influence the drug’s commercial potential as the company pursues FDA approval.
- Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial statnews.com
- Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD Yahoo Finance
- OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds Stocktwits
- Ocular eyes superiority claim after Axpaxli success in wet AMD study, but shares fall FirstWord Pharma
- Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA BioSpace
Want the full story? Read the original reporting
Read on statnews.com